Objective. To provide population-based estimates of relative risk of SLE and other autoimmune diseases (ADs) in relatives of SLE patients.
Introduction
SLE is a complex autoimmune disease (AD) that develops through the interplay of genetic, epigenetic and environmental factors [1] . Heritability has been estimated to be 4466% [24] , but due to the low disease prevalence a large proportion of cases appear sporadic [3] . SLE prevalence has been reported to be 0.020.07% in unselected populations around the world [5] and 0.045% in Denmark [6] . While familial aggregation of SLE and other ADs occurs in families of SLE patients, the associated relative risks remain insufficiently investigated. Knowledge from population-based studies about the relative risk of SLE and other ADs among relatives of SLE patients may be helpful when counselling patients with SLE and their families about the risk of familial autoimmunity. Therefore, we undertook a nationwide cohort study in Denmark to assess the relative risk of SLE and other ADs in relatives of SLE patients.
Methods

Cohort
The cohort consisted of all Danish residents born 1 January 1950 or later and identified through the Civil Registration System, which is a continuously updated national demographic database in operation since 1968 [7] . Using the unique identification number assigned to all Danish residents at birth or date of immigration, relatives were identified through the parental link, allowing identification of parents, children, siblings and half-siblings residing in Denmark since 1950. Through the parental link to grandparents, we further identified grandparents, grandchildren, aunts/uncles, nieces/nephews, cousins and halfaunts/half-uncles. Twins were identified as individuals born by the same mother on the same day (±1). Through linkage to the Danish Twin Registry, monozygotic and dizygotic twins were distinguished based on self-reported physical similarity [8] , which has previously been shown to be >95% accurate [9] . The study was approved by the Danish Data Inspection Board (approval nos 2008-41-2374 and 2008-54-0472) and involved no patient contact.
ADs
Information regarding SLE and other ADs was obtained through linkage to the National Patient Register for recorded diagnoses in connection with inpatient hospital contacts from 1 January 1977, and outpatient hospital contacts since 1 January 1995, until 31 July 2013 [10] . Recorded diagnoses of ADs were retrieved under diagnostic codes according to the International Classification of Diseases, 8th (period 197793, ICD-8) In subsequent analyses, we focused on the relative risk of SLE and any AD in individual categories of first-, second-and third-degree relatives of SLE patients. We also calculated relative risks of SLE, RA, autoimmune thyroid disease, multiple sclerosis, IBD, psoriasis, type 1 diabetes mellitus, other ADs, any AD and any AD excluding SLE in first-degree relatives and in the combined category of second-or third-degree relatives.
Statistical analyses
We followed cohort members for SLE and other ADs from 1 January 1977, date of birth or immigration, whichever came last. Family disposition to SLE was treated in a timedependent hierarchical manner. From the date of first hospital contact with an SLE diagnosis in a cohort member, all family members were considered exposed to a first-, second-or third-degree relative with SLE, depending on their particular family relation with the affected relative. In families where more than one family member was diagnosed with SLE during follow-up, all relatives' exposure statuses were reclassified on the date of first SLE hospitalization in their most recently affected relative. For example, a woman born in 1955 would be followed as unexposed from 1 January 1977, until 23 March 1980, when her cousin was first hospitalized with SLE. From that date, she would be followed as an exposed person with a third-degree relative with SLE until 8 August 1999, when her mother was hospitalized with SLE. From that date and until 31 July 2013, she would be followed as an exposed person with a first-degree relative affected with SLE. Subsequent SLE diagnoses in more remotely related family members would not lead to a downward change in exposure category. In the analysis of any AD excluding SLE, all cohort members (i.e. both relatives of SLE patients and unexposed cohort members in the general population) were followed for AD until the day before a potential SLE diagnosis, at which point follow-up was censored.
The relative risk of SLE and other ADs associated with having an SLE-affected relative was evaluated by means of hazard ratios (HRs) with 95% CIs obtained in Cox proportional hazards regression analyses using age in days as the underlying timescale. All analyses were stratified according to sex and birth year, thereby taking into account possible effects of sex, age and calendar period. In a robustness analysis, we stratified by number of relatives in each relation category (i.e. first-, second-or thirddegree relatives) in a time-dependent manner, thereby taking into account any possible influence on HRs of family size differences among cohort members. In another robustness analysis, we aimed at reducing any impact of diagnostic misclassification by considering only patients who had two or more hospital contacts for the same AD diagnosis; here the second hospital contact served as the date of diagnosis. HRs with 95% CIs excluding unity were considered statistically significant. All analyses were carried out using SAS version 9.4, apart from the twin analyses, which were carried out in STATA 13.1.
Results
Cohort
The cohort comprised 5 237 319 persons (2 560 155 women and 2 677 164 men) born since 1 January 1950, who were followed for a mean period of 22. 
HRs for specific ADs in relatives of SLE patients
Overall, cohort members with an SLE-affected firstdegree relative were at a 10.3-fold elevated risk of SLE (HR = 10.3; 95% CI: 8.25, 12.9), which was less pronounced, yet clearly elevated, among those with SLEaffected second-or third-degree relatives (HR = 3.60; 95% CI: 2.20, 5.90) ( Table 1 ). The overall risk of any AD was significantly increased among both first-degree (HR = 1.51; 95% CI: 1.41, 1.62) and second-or third-degree relatives of SLE patients (HR = 1.28; 95% CI: 1.18, 1.39). Even after censoring individuals at the moment of an SLE diagnosis, the risk of any AD excluding SLE remained significantly increased in both first-degree (HR = 1.44; 95% CI: 1.34, 1.55) and second-or third-degree relatives of SLE patients (HR = 1.26; 95% CI: 1.16, 1.37).
The risk of developing RA was significantly increased among cohort members with SLE-affected first-degree relatives (HR = 1.64; 95% CI: 1.35, 1.99), and less so among those with second-or third-degree relatives (HR = 1.36; 95% CI: 0.98, 1.87). Although there was a slightly increased risk of autoimmune thyroid disease among individuals with SLE-affected first-degree (HR = 1.16; 95% CI: 0.93, 1.43) and second-or third-degree relatives (HR = 1.29; 95% CI: 0.96, 1.72), this was not statistically significant. Multiple sclerosis risk was unchanged in cohort members with SLE-affected first-degree relatives (HR = 0.99; 95% CI: 0.70, 1.38), but among those with SLEaffected second-or third-degree relatives the HR was 1.64 (95% CI: 1.11, 2.43). Furthermore, first-degree relatives of SLE patients had slightly increased risks of IBD (HR = 1.21; 95% CI: 1.02, 1.43) and type 1 diabetes mellitus (HR = 1.23; 95% CI: 1.01, 1.48). The risk of other ADs was significantly increased among individuals with SLE-affected first-degree (HR = 2.08; 95% CI: 1.88, 2.31) and second-or third-degree relatives (HR = 1.38; 95% CI: 1.23, 1.54) ( Table 1) .
In a robustness analysis, we stratified by the cohort members' numbers of first-, second-and third-degree relatives in a time-dependent manner to account for any possible influence of family size differences. Results were essentially unchanged compared with those presented in Table 1 , implying that family size was not a confounder (data not shown). To further ascertain the validity of our findings, we performed another robustness analysis restricted to AD diagnoses recorded in connection with at least two independent hospital contacts in the same patient. Generally, the findings in Table 1 were confirmed. The overall risk of any AD among individuals with a firstdegree relative with SLE remained significantly elevated (HR = 1.65; 95% CI: 1.48, 1.85). Particularly high HRs were observed for SLE (HR = 14.4; 95% CI: 10.4, 19.9), RA (HR = 2.28; 95% CI: 1.69, 3.08) and the combined group of other ADs (HR = 2.24; 95% CI: 1.87, 2.70), and the elevated risk of type 1 diabetes mellitus was confirmed (HR = 1.36; 95% CI: 1.04, 1.78). The observed lack of an association between SLE in first-degree relatives and risk of multiple sclerosis (HR = 1.10; 95% CI: 0.69, 1.78) or autoimmune thyroid disease (HR = 1.27; 95% CI: 0.87, 1.87) was confirmed, and the HR of multiple sclerosis in second-or third-degree relatives remained increased (HR = 1.77; 95% CI: 0.98, 3.20), although it was no longer statistically significant.
HRs for SLE and any AD in relatives of SLE patients by specific family relationship Overall, the risk of SLE among individuals with an SLEaffected co-twin was markedly elevated (HR = 76.3; 95% CI: 24.6, 237), with HRs of 85.7, 49.7 and 116 for monozygotic twins, dizygotic twins and twins of unknown zygosity, respectively ( Table 2 ). The risk of any AD in individuals with an SLE-affected co-twin was almost three times increased (HR = 2.72; 95% CI: 1.23, 6.02), with corresponding HRs of 3.84, 0.95 and 4.42 for monozygotic twins, dizygotic twins and twins of unknown zygosity, respectively.
For non-twin first-degree relatives, HRs of developing SLE ranged between 8.72 for parents and 17.0 for children of SLE patients ( HRs of SLE and any AD by number of SLE-affected first-degree relatives
The risk of SLE and any AD was positively associated with the number of SLE-affected first-degree relatives. Among cohort members with one SLE-affected first-degree relative, 78 individuals developed SLE (HR = 9.84; 95% CI: 7.85, 12.3), while among cohort members with two or more first-degree relatives with SLE, two individuals were subsequently diagnosed with SLE (HR = 61.1; 95% CI: 15.3, 245).
The HR for any AD among individuals with one SLEaffected first-degree relative was 1.50 (95% CI: 1.40, 1.61; n = 781), whereas the HR was 2.09 (95% CI: 0.80, 5.44; n = 4) for cohort members with two or more SLEaffected first-degree relatives.
HRs of SLE and any AD according to sex
In sex-specific analyses of AD risk, female cohort members with an SLE-affected relative were at an 8-fold elevated risk of developing SLE, regardless of the sex of the affected relative. For male cohort members with an SLEaffected female or male relative, HRs were 4.67-fold (95% CI: 2.21, 9.88) and 10.3-fold (95% CI: 3.31, 32.2) elevated, respectively (Table 3) . Female cohort members with an SLE-affected female or male relative had a 1.47 and 1.29 times increased risk of any AD, respectively. Male cohort members with an SLE-affected female or male relative with SLE had a 1.35 and 1.29 times increased risk of any AD, respectively (Table 3) .
Discussion
In the present study, we assessed the impact of having a family history of SLE on the risk of developing an AD in a population-based Danish cohort. Salient findings were that the risk of developing any AD was significantly 51% and 28% elevated in individuals with a first-degree or second-or third-degree relative with SLE, respectively. The risk was substantially elevated for SLE, but also for RA, IBD, type 1 diabetes mellitus and the combined group of other ADs in individuals with an SLE-affected firstdegree relative. Individuals who had a co-twin or more than one first-degree relative with SLE were at a 76 and 61 times increased risk of developing SLE, respectively.
There was no clear influence of the sex of the SLE-affected family member on the risk of SLE, although male cohort members with an SLE-affected male relative were at a 10-fold elevated relative risk of developing SLE as Hazard ratios were calculated for first-, second-or third-degree relatives of patients with SLE using cohort members without known relatives affected by SLE as reference. HR: hazard ratio; NA: not applicable.
www.rheumatology.oxfordjournals.org compared with the 8-fold increased risk in female cohort members. In one previous cohort study, there was a trend that men with SLE-affected male relatives were at a higher risk of SLE [3] , but such an effect was not clear in the present study. In another Danish cohort study examining the risk of SLE in offspring of SLE-affected parents, the relative risk of SLE in female offspring was 14, which is comparable with the 17-fold increased risk of SLE in children of SLE-affected parents in the present study. Unfortunately, there were too few SLE cases to assess risk of SLE in male offspring in that study [14] . Previous studies have reported that 1.312% of SLE patients have a first-degree relative with SLE [13, 1518] . In the present population-based study, 80 (2.2%) of the total of 3612 cases of SLE occurred in cohort members with at least one SLE-affected firstdegree relative, which is comparable with the 1.3% SLE prevalence in first-degree relatives of SLE patients found in another population-based cohort study [3] , while in previous family studies, SLE prevalence in first-degree relatives of SLE patients tended to be higher [1520] . Reasons for this discrepancy could be that former family studies potentially selected SLE patients with more serious disease or with known familial aggregation of SLE (theoretically reflecting a greater influence of genetic predisposition). Family studies may further have been subject to recall bias when based on personal interviews.
Other ADs have also been found to co-aggregate with SLE, with 1427% of SLE patients having a first-, secondor third-degree relative with some kind of AD [13, 15, 1720] . Especially RA seems to be overrepresented in previous family studies, with between 2.2 and 11% of SLE patients having a relative with RA, although these studies did not take into account the prevalence of RA in the general population. Likewise, it is unclear to what degree other ADs were overrepresented in relatives of SLE patients [13, 15, 1720] . Only one previous cohort study seems to be comparable with the present study in this respect [3] , with a 2.6-fold increased risk of RA and multiple sclerosis in first-degree relatives of SLE patients in Taiwan, as well as a 68% increased risk of type 1 diabetes mellitus and a 39% increased risk of IBD, although the latter was not statistically significant. In the present study, HRs of RA, type 1 diabetes mellitus and IBD were all lower in first-degree relatives than relative risk estimates previously reported, but they were nonetheless significantly increased. The risk of multiple sclerosis was increased in second-or third-degree relatives of SLE patients, but not in first-degree relatives. However, the increased risk of multiple sclerosis in second-or thirddegree relatives was no longer statistically significant in robustness analyses requiring two independent hospital contacts for the disease to define a case, so it cannot be excluded that these findings were due to chance.
Even when disregarding the selected seven major ADs (SLE, RA, autoimmune thyroid disease, multiple sclerosis, IBD, psoriasis and type 1 diabetes mellitus), both firstdegree and second-or third-degree relatives of SLE patients were at a significantly increased risk of other ADs.
This potentially indicates that besides having an increased risk of specific ADs, relatives of SLE patients may be at a more diffusely increased risk of AD development.
A cross-phenotype meta-analysis of seven selected ADs (coeliac disease, Crohn's disease, multiple sclerosis, psoriasis, RA, SLE and type 1 diabetes mellitus) suggested that nearly half of the susceptibility loci identified in previous genome-wide association studies were overlapping between diseases [21, 22] , and suggested clustering of certain ADs with specific single-nucleotide polymorphisms, for instance SLE clustering with RA and type 1 diabetes mellitus for single-nucleotide polymorphisms such as STAT4, IRF5 and TNFAIP3. The present study indicates that ADs other than the seven selected major ADs included may potentially also cluster with SLE within families, but this remains to be seen in genome-wide association studies of autoimmunity.
In the present study, the HR of SLE as well as ADs dropped markedly between each relationship category. Thus, HRs of SLE fell from 75 in twins to 10 in firstdegree non-twin relatives, to 3.4 in second-degree relatives and 5 in third-degree relatives. A similar pattern was apparent for any AD, with HRs dropping from 2.7 in twins, to 1.5 in first-degree non-twin relatives to 1.3 in secondand third-degree relatives. The risk reduction in less closely related family members is consistent with a multifactorial inheritance, which is apparent for SLE, as well as for any AD, although on a smaller scale. In a subset analysis, we found that the HR of any AD was only marginally changed when excluding SLE, which suggests that the increased overall risk of any AD is not explained by the markedly increased relative risk of SLE. The mode of inheritance of SLE has been looked at in only a few studies, the findings of which have been indicative of a polygenic additive inheritance of SLE [4, 13] . To the best of our knowledge, however, ours is the first study to suggest that the same pattern of familial aggregation may be present for ADs more generally.
Only a few studies have looked at familial aggregation of SLE on a nationwide level. In a recent cohort study from Taiwan, 18 283 persons were identified as having SLE. Among these, 607 first-degree relatives had SLE, corresponding to an overall 17 times increased risk of SLE in first-degree relatives and a 315 times increased risk in twins [3] . The cohort was based on national health insurance data, where the insured person had to claim relatives as dependents. Hence, 20% of the cohort members were registered alone without any identifiable relative. However, the diagnosis of SLE could only be agreed upon by an expert panel from the Taiwan National Health Insurance, so the case definition was expected to be stringent, although less severe cases may have been missed.
Our register-based study also relied on routinely collected information about patients in the National Patient Register, which is registered in an unbiased manner and contains information about hospital contacts for the entire Danish population since 1977 [10] . The possibility of diagnostic misclassification is always a caveat in register-based studies. However, we have used registry data on Danish patients with SLE and other ADs in several prior studies [2327] , and a recently published paper indicated good validity of SLE diagnoses in the Danish National Patient Register. Of 208 randomly selected patients above the age of 18 years with at least one registered ICD-10 code for SLE, 69% fulfilled the ACR classification criteria; among SLE patients with at least 1 year of outpatient follow-up or at least two inpatient admissions during the first year of follow-up, 86% fulfilled the ACR criteria [6] .
While established family relations among cohort members are expected to be accurate, because they are based on high-quality administrative data from the Civil Registration System, the degree of completeness for various categories of relatives will vary depending on the degree of relatedness. While cohort members, who were all born 1950 or later, will have links to close relatives alive at the start of follow-up in 1977 [7] , links to more distant relatives such as aunts/uncles, nephews/nieces or cousins depend on the availability of parental links to the grandparents. Importantly, however, while incomplete links to relatives might theoretically render our HRs slightly conservative, our robustness analysis in which we took family size into account as a stratification variable suggests that such incomplete links had only limited impact on our findings. Previous cohort studies of familial aggregation in autoimmunity are few and have mostly focused on first-degree relatives of SLE patients. The present population-based cohort study of AD risk among relatives of SLE patients takes a prospective approach, which provides results relevant to the clinical situation where a newly diagnosed patient asks about the family's future risk of SLE or other ADs. Previous studies have not systematically looked at the risk of SLE and other ADs in second-or third-degree relatives apart from one study [13] , which also found that there is a clearly elevated risk in more remote relatives.
All in all, our study shows that a family history of SLE constitutes a major risk factor for subsequent development of SLE and other ADs in a manner that depends on the degree of relatedness. Our findings may be useful when counselling families affected by SLE. Many close family members of SLE patients may find it reassuring to learn that although their relative risk of developing SLE themselves is markedly elevated, their absolute risk remains low; according to the present national cohort study only around 2% of individuals with an SLE-affected non-twin first-degree relative developed SLE during an average of 22 years of follow-up.
